Jump to content
World's Largest Herpes Support Group


Sign in to follow this  
StayingUpbeat

The Next HSV-529 Live Attenuated Therapeutic Vaccine Clinical Trial Has Begun

Recommended Posts

Shubhherpe
On 8/11/2020 at 5:15 PM, themotion said:

@Cas9 Hey, Sorry to bother you, but can you share your opinion on the content quoted above. Hope all is well.

 

Thank you

Herpes expert Josh bloom  mentioned that developing a theraupatic Vaccine will be much easier than developing a prophylactic one. Also most of the active trials are for theraupatic use and also most of the upcoming trials would be theraupatic only. 

Share this post


Link to post
Share on other sites
Voyager2

Don't forget there are two promising vaccines on the prophylactic front (but only pre-clinical):

The Trivalent vaccine worked well on guinea pigs:

 https://pubmed.ncbi.nlm.nih.gov/32347775/

The Einstein (Xvax) vaccine also has a ways to go:

https://x-vax.com/

The fact HSV529 is in yet another clinical trial is good news for herpsters. 

Share this post


Link to post
Share on other sites
thethinker82

Yes, that sentence is in that form not correct. The main current research focus seems to be still for therapeutic and not prophylactic HSV vaccines.

However, but I stand for the other part. According to the information I found, it seems to be much easier to develop a prophylactic HSV vaccine than a therapeutic one. This is the normal way how vaccines work, prophylactic. We can see this in almost any vaccinable disease. There seems to exist at the moment no single therapeutic vaccine at the market.

Yes, there are some in development. And some are almost finished. The first ever therapeutic vaccine may be VGX-3100 from INOVIO. It is a DNA based human papillomavirus (HPV) vaccine which targets the squamous intraepithelial lesions on the surface of the cervix. And while we're on HPV, it looks that the originally prophylactic vaccine Gardasil 9 can be used for certain forms of squamous cell carcinoma (skin cancer). There are some really amazing reports available about the complete cure of a 97 year old person. That extraordinary healing was achieved through several intramuscular & intratumoral administration of Gardasil 9. ;)

Back to the original topic. The Perelman HSV-2 Trivalent HSV candidate is a prophylactic HSV vaccine. A very informative 2017 interview of the lead researcher Harvey Friedman (with Josh Bloom) can be found at the following link.

https://www.acsh.org/news/2017/10/11/herpes-vaccine-update-interview-penns-dr-harvey-friedman-11940

That interview also reflects the therapeutic and prophylactic vaccine approach. Particularly interesting is the statement of Dr. Harvey Friedman regarding the effectiveness of his trivalent HSV vaccine candidate. He notes that it will not work well enough to be therapeutic. It needs an additional mechanism called "Prime and Pull" approach. We are now in 2020 and this may be true also for most other current HSV vaccine candidates.

And finally, according to the current known trial results, HSV-529 may be the perfect candidate for a prophylactic HSV vaccine. Someone should tell this Sanofi. ;)

Share this post


Link to post
Share on other sites
Runner278

I got some unfortunate but not unexpected news this morning:

Dear Sir or Madam: 

Thank you for your e-mail in which you expressed interest in the clinical trial NCT04222985, HSV15, Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2.

Our role is to inform patients which institutions are recruiting for clinical trials sponsored by Sanofi in their geographic region.

 Unfortunately, recruitment in this study has been put on hold.  is suspended for one site (For your information, participation in the Part B is expected to be started in the end of 2022.

Share this post


Link to post
Share on other sites
themotion
6 hours ago, Runner278 said:

I got some unfortunate but not unexpected news this morning:

Dear Sir or Madam: 

Thank you for your e-mail in which you expressed interest in the clinical trial NCT04222985, HSV15, Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2.

Our role is to inform patients which institutions are recruiting for clinical trials sponsored by Sanofi in their geographic region.

 Unfortunately, recruitment in this study has been put on hold.  is suspended for one site (For your information, participation in the Part B is expected to be started in the end of 2022.

Firstly, I applaud your courage that you're willing to participate! Thank you so much.

 

Second, I'm stuck on the words "geographic region". Could this only be because you're not in there preferred proximity?

 

Also, I've seen the HSV-529 and read plenty about it, but what is "HSV15"

 

Keep well and thanks again!

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.